BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL-TO-MILD) ALZHEIMER'S DISEASEKaycee Sink, Francis Warren,Jillian Smith, Andres Schneider,Reina N. Fuji,Angelica Quartino,Howard Mackey,Michael Rabbia, Susan Yule,Paulo Fontoura,Rachelle Doody,Susanne OstrowitzkiAlzheimers & Dementia(2019)引用 2|浏览71暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要